Fortress Biotech News

Express News | Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of Cmv in Patients Undergoing Liver Transplantation

ReutersMay 14 08:30 ET

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

Study is evaluating whether Triplex is safe and effective in improving the outcomes of liver transplant recipients .

GlobeNewswireMay 14 08:30 ET

Journey Medical 1Q Rev $13M >DERM

Journey Medical 1Q Rev $13M >DERM

Dow JonesMay 13 16:03 ET

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President

GlobeNewswireMay 13 08:30 ET

Express News | Checkpoint Therapeutics Inc - Qtrly Shr Loss $0.33

ReutersMay 10 08:31 ET

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first

GlobeNewswireMay 10 08:30 ET

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Dow JonesMay 10 08:30 ET

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Dow JonesMay 10 08:30 ET

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of

GlobeNewswireMay 7 08:30 ET

Express News | Mustang Bio Announces Closing of $4 Million Public Offering

ReutersMay 2 16:01 ET

Express News | Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

ReutersMay 1 16:01 ET

Express News | Mustang Bio Inc- Pricing of Public Offering of Aggregate of 16.88 Mln Shares, Warrants at Combined Price of $0.237 per Share and Warrant

ReutersApr 29 20:09 ET

Express News | Mustang Bio Announces Pricing of $4 Million Public Offering

ReutersApr 29 20:00 ET

Express News | Avenue Therapeutics : Reverse Stock Split Is Intended to Bring the Co Into Compliance With Nasdaq’s $1.00 per Share Minimum Bid Price Requirement

Moomoo 24/7Apr 24 07:32 ET

Express News | Avenue Therapeutics Inc: Announced That It Will Effect a 1-for-75 Reverse Split of Its Issued and Outstanding Common Stock

Moomoo 24/7Apr 24 07:31 ET

Express News | Avenue Therapeutics Announces Reverse Stock Split

Moomoo 24/7Apr 24 07:30 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersTrevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. Mustang Bio (NASDAQ:MBIO) stock increased by 1

BenzingaApr 17 16:31 ET

Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments

TipRanksApr 9 06:17 ET

Fortress Biotech Q4 EPS $(0.53) Beats $(1.97) Estimate, Sales $19.95M Beat $14.89M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1.97) by 73.1 percent. This is a 55.83 percent increase over losses of $(1.

BenzingaMar 28 23:33 ET

Fortress Biotech GAAP EPS of -$8.47 Beats by $0.64, Revenue of $84.51M Beats by $4.83M

Seeking AlphaMar 28 16:57 ET